@article{a8e55ea16efb44c4805eae60ef345a3a,
title = "Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia",
author = "F. Ravandi and {Arana Yi}, C. and Cortes, {J. E.} and M. Levis and S. Faderl and G. Garcia-Manero and E. Jabbour and M. Konopleva and S. O'Brien and Z. Estrov and G. Borthakur and D. Thomas and S. Pierce and M. Brandt and K. Pratz and R. Luthra and M. Andreeff and H. Kantarjian",
note = "Funding Information: This study was supported in part by the National Institutes of Health through the University of Texas MD Anderson Cancer Center Support Grant CA016672 and by an educational grant from Onyx/Bayer Pharmaceuticals. Funding Information: FR has received research funding from Bayer and Onyx Pharmaceuticals and has been a member of advisory boards with Bayer and Onyx Pharmaceuticals. The remaining authors declare no conflict of interest.",
year = "2014",
month = jul,
doi = "10.1038/leu.2014.54",
language = "English (US)",
volume = "28",
pages = "1543--1545",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",
}